Nuveen
ABUS icon

Nuveen’s Arbutus Biopharma ABUS Stock Holding History

Nuveen’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.38M Buy
496,609
+237,592
+92% +$1.04M ﹤0.01% 2485
2026
Q1 		$1.17M Buy
259,017
+1,083
+0.4% +$4.74K ﹤0.01% 2513
2025
Q4 		$1.24M Hold
257,934
– – ﹤0.01% 2509
2025
Q3 		$1.17M Sell
257,934
-153,322
-37% -$563K ﹤0.01% 2549
2025
Q2 		$1.27M Buy
411,256
+97,949
+31% +$325K ﹤0.01% 2501
2025
Q1 		$1.09M Hold
313,307
– – ﹤0.01% 2601
2024
Q4 		$1.02M Hold
313,307
– – ﹤0.01% 2699
2024
Q3 		$1.21M Hold
313,307
– – ﹤0.01% 2675
2024
Q2 		$968K Buy
313,307
+19,151
+7% +$57.5K ﹤0.01% 2740
2024
Q1 		$759K Hold
294,156
– – ﹤0.01% 2813
2023
Q4 		$735K Buy
294,156
+2,134
+0.7% +$4.18K ﹤0.01% 2867
2023
Q3 		$593K Sell
292,022
-1,701
-0.6% -$3.57K ﹤0.01% 2785
2023
Q2 		$676K Buy
293,723
+19,266
+7% +$50.1K ﹤0.01% 2831
2023
Q1 		$832K Sell
274,457
-15,644
-5% -$44.1K ﹤0.01% 2670
2022
Q4 		$675K Sell
290,101
-36,039
-11% -$86.2K ﹤0.01% 2812
2022
Q3 		$623K Sell
326,140
-1,185
-0.4% -$2.79K ﹤0.01% 2904
2022
Q2 		$887K Sell
327,325
-1,278,189
-80% -$3.27M ﹤0.01% 2841
2022
Q1 		$4.62M Sell
1,605,514
-406,295
-20% -$1.24M ﹤0.01% 2103
2021
Q4 		$7.89M Buy
2,011,809
+892,198
+80% +$3.47M ﹤0.01% 1830
2021
Q3 		$4.87M Buy
1,119,611
+893,599
+395% +$2.98M ﹤0.01% 2225
2021
Q2 		$685K Buy
+226,012
New +$700K ﹤0.01% 3119

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Nuveen's ABUS Position: Q2 2026 in Review

Nuveen increased its Arbutus Biopharma (ABUS) stake by 92% in Q2 2026, buying an estimated $1.04M and bringing the position to 496,609 shares worth $2.38M. The position accounts for ﹤0.01% of the portfolio, ranked #2485.

Nuveen first reported a position in ABUS in Q2 2021 and has held it in 21 quarters since. The position peaked at $7.89M in Q4 2021. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Nuveen held 496,609 shares of Arbutus Biopharma worth $2.38M as of Q2 2026.
  • Nuveen bought 237,592 Arbutus Biopharma shares in Q2 2026, an estimated $1.04M.
  • Arbutus Biopharma made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2485 holding.
  • Nuveen first reported a position in Arbutus Biopharma in Q2 2021 and has held it in 21 quarters since.
  • Nuveen's Arbutus Biopharma position peaked at $7.89M in Q4 2021.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.